Comments
Cipla on Friday announced the launch of its proprietary respiratory inhalation therapy product ‘Niveoli’ in India. Niveoli addresses an unmet need associated with obstructive airway diseases such as asthma and chronic obstructive pulmonary disorder, Cipla said in a BSE filing. Shares of Cipla gained 1.84 per cent at ₹554.35 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.